Skip to main content

Advertisement

SpringerLink
Log in

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

A Correction to this article was published on 06 July 2018

This article has been updated

Abstract

In paroxysmal nocturnal hemoglobinuria (PNH), various symptoms due to intravascular hemolysis exert a negative impact on patients’ quality of life (QOL). To determine clinical factors related with improvements in QOL in PNH patients treated, we analyzed changes in QOL scales in PNH patients treated with eculizumab based on data collected from post-marketing surveillance in Japan. Summary statistics were obtained using figures from QOL scoring systems and laboratory values, and evaluated by t test. One-year administration of eculizumab improved the most QOL items in comparison with the baseline. In particular, significant improvement of EORTC QLQ-C30 was observed in fatigue, dyspnea, physical function, and global health status. Canonical correlation analysis revealed a high correlation between QOL and laboratory values. Changes in serum lactate dehydrogenase (LDH) and hemoglobin showed strong correlations with QOL improvement. Quality of life improvement was independent of patients’ baseline characteristics of co-occurrence of bone marrow failure (BMF), or the degree of LDH. In this analysis, we found that the degree of QOL improvement was independent of the baseline LDH before eculizumab treatment and of co-occurrence of BMF. Paroxysmal nocturnal hemoglobinuria patients who have not received eculizumab treatment due to mild hemolysis may benefit from eculizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Change history

  • 06 July 2018

    In the original publication of this article, Tables 2, 3 and 4 were published incorrectly. The corrected tables 2, 3 and 4 are given in the following pages.

References

  1. Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, Kitani T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249–55.

    Article  PubMed  CAS  Google Scholar 

  2. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.

    Article  PubMed  CAS  Google Scholar 

  3. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–709.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99:922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Almeida AM, Bedrosian C, Cole A, Muus P, Schrezenmeier H, Szer J, et al. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017;47:1026–34.

    Article  PubMed  CAS  Google Scholar 

  6. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–43.

    Article  PubMed  CAS  Google Scholar 

  7. Brodsky RA, Young NS, Antonoli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7.

    Article  PubMed  CAS  Google Scholar 

  8. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36–46.

    Article  PubMed  CAS  Google Scholar 

  9. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98:406–16.

    Article  PubMed  CAS  Google Scholar 

  10. Ninomiya H, Obara N, Chiba S, Usuki K, Nishiwaki K, Matsumura I, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548–58.

    Article  PubMed  CAS  Google Scholar 

  11. Cella D. Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston IL, Version 4. 1997.

  12. Yoshimura A, Kobayashi K, Fumimoto H, Fujiki Y, Eremenco S, Kudoh S. Cross-cultural validation of the Japanese functional assessment of cancer therapy-anemia (FACT-An). J Nippon Med Sch. 2004;71:314–22.

    Article  PubMed  Google Scholar 

  13. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

    Google Scholar 

  14. Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H, Yoneda S, et al. A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer. 1998;34:810–5.

    Article  PubMed  CAS  Google Scholar 

  15. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002;24:547–61.

    Article  PubMed  Google Scholar 

  16. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.

    Article  PubMed  CAS  Google Scholar 

  17. Groth M, Singer S, Niedeggen C, Petermann-Meyer A, Röth A, Schrezenmeier H, et al. Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II. Ann Hematol. 2017;96:171–81.

    Article  PubMed  CAS  Google Scholar 

  18. Weitz I, Meyers G, Lamy T, Cahn JY, Uranga MT, García Vela JA, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Int Med J. 2013;43:298–307.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all participating physicians and registered patients who took part in this surveillance study. We are grateful to Dr. Yasuo Ohashi of Dep. Integrated Science and Engineering for Sustainable Society, Chuo University for special advice on research design including statistical analysis. This study was sponsored by Alexion, and Alexion was involved in the process of the study design, data collection, analysis and manuscript preparation. Alexion approved the content of the manuscript and the submission of the manuscript for publication.

Funding

Logistical and financial cost for the post-marketing surveillance of eculizumab including statistical analysis was provided by Alexion Pharma GK.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

    Yasutaka Ueda, Jun-ichi Nishimura & Yuzuru Kanakura

  2. Japan PNH Study Group, Tokyo, Japan

    Yasutaka Ueda, Naoshi Obara, Yuji Yonemura, Hideyoshi Noji, Takayuki Ikezoe, Shigeru Chiba, Yoshinobu Kanda, Tatsuya Kawaguchi, Tsutomu Shichishima, Hideki Nakakuma, Shinichiro Okamoto, Jun-ichi Nishimura, Yuzuru Kanakura & Haruhiko Ninomiya

  3. Department of Hematology, University of Tsukuba, Tsukuba, Japan

    Naoshi Obara

  4. Department of Transfusion Medicine and Cell Therapy, Kumamoto University Hospital, Kumamoto, Japan

    Yuji Yonemura

  5. Department of Hematology, Fukushima Medical University, Fukushima, Japan

    Hideyoshi Noji, Takayuki Ikezoe & Tsutomu Shichishima

  6. Department of Stem Cell Transplantation, Niigata University Hospital, Niigata, Japan

    Masayoshi Masuko

  7. Department of Hematology, Niigata Prefectural Shibata Hospital, Shibata, Japan

    Yoshinobu Seki

  8. Department of Hematology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami-Uonuma, Japan

    Yoshinobu Seki

  9. Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan

    Katsuya Wada

  10. Alexion Pharma G.K, Tokyo, Japan

    Takahisa Matsuda & Hirozumi Akiyama

  11. Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Shigeru Chiba

  12. Division of Hematology, Jichi Medical University, Shimotsuke, Japan

    Yoshinobu Kanda

  13. Departments of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan

    Tatsuya Kawaguchi

  14. Kagoshima Tokusyukai Hospital, Kagoshima, Japan

    Hideki Nakakuma

  15. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Shinichiro Okamoto

  16. Department of Medical Sciences, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Haruhiko Ninomiya

Authors
  1. Yasutaka Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoshi Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuji Yonemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideyoshi Noji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayoshi Masuko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshinobu Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsuya Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takahisa Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirozumi Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takayuki Ikezoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shigeru Chiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshinobu Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tatsuya Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Tsutomu Shichishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Hideki Nakakuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Jun-ichi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yuzuru Kanakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Haruhiko Ninomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haruhiko Ninomiya.

Ethics declarations

Conflict of interest

Dr. Kawaguchi reported personal fees from Alexion Pharma G.K., outside the submitted work; Dr. Ueda reported personal fees from Kyowa Hakko Kirin Co.Ltd. and from Celgene, outside the submitted work; Dr. Shichishima and Dr. Yonemura, report grants from Alexion Pharma G.K., outside the submitted work; Dr. Ueda, Dr. Nishimmura, Dr. Ninomiya report grant and personal fees from Alexion Pharma G.K., during the conduct of the study; Dr. Chiba report grand from Alexion Pharma G.K., during the conduct of the study. Dr. Okamoto reports grants from Alexion Pharma G.K. and from Chugai Pharmaceutical Co. Ltd., outside the submitted work. Dr. Kanakura reports grants from Alexion Pharma G.K. and from Chugai Pharmaceutical Co. Ltd. Dr. Obara, Dr. Seki, Dr. Kanda, Dr. Nakakuma, Dr. Ikezoe, and Dr. Masuko, Dr. Noji and Dr. Wada have nothing to declare; Dr. Matsuda and Mr. Akiyama report other from Alexion Pharma G.K., outside the submitted work; Employee of Alexion Pharma G.K. and Stock/stock options in the company.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ueda, Y., Obara, N., Yonemura, Y. et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 107, 656–665 (2018). https://doi.org/10.1007/s12185-018-2409-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-018-2409-3

Keywords

Search

Navigation